AMGEN INC

AMGN · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $184.7B · 31,500 employees
132
SEC Filings
$351.02
Close 2026-04-10
31,500
Employees

Business Summary

PART I Amgen Inc. (including its subsidiaries, referred to as Amgen, the Company, we, our or us) discovers, develops, manufactures and delivers innovative medicines to fight some of the worlds toughest diseases. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that dramatically improve peoples lives, while also reducing the social and economic burden of disease. We helped launch the biotechnology industry more than 45 years ago and have grown to be ...

Latest Stock Quote

AMGN 2026-04-10 $351.02 O:$357.46 H:$357.46 L:$349.75 Vol:2.3M VWAP:$351.8918
origin leaf: 9638092be70042ae9e564842250258205efd9b493296d1e11cace00afe9634d9

Next Earnings

expected 2026-08-06

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionAMGNdiscussed_in_filing Cybersecurity
topic_mentionAMGNdiscussed_in_filing Regulation
topic_mentionAMGNdiscussed_in_filing Sovereign & Government
topic_mentionAMGNdiscussed_in_filing Cybersecurity
topic_mentionAMGNdiscussed_in_filing Regulation
topic_mentionAMGNdiscussed_in_filing Sovereign & Government
topic_mentionAMGNdiscussed_in_filing Healthcare & Bio
topic_mentionAMGNdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-132025-12-310000318154-26-000010EDGAR104K words
2025-02-142024-12-310000318154-25-000010EDGAR—
2024-02-142023-12-310000318154-24-000011EDGAR—
2023-02-092022-12-310000318154-23-000017EDGAR—
2022-02-162021-12-310000318154-22-000010EDGAR—
2021-02-092020-12-310000318154-21-000010EDGAR—
2020-02-122019-12-310000318154-20-000017EDGAR—
2019-02-132018-12-310000318154-19-000008EDGAR—
2018-02-132017-12-310000318154-18-000004EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-052025-09-300000318154-25-000072EDGAR38K words
2025-08-062025-06-300000318154-25-000056EDGAR—
2025-05-022025-03-310000318154-25-000020EDGAR—
2024-10-312024-09-300000318154-24-000044EDGAR—
2024-08-072024-06-300000318154-24-000035EDGAR—
2024-05-032024-03-310000318154-24-000020EDGAR—
2023-10-312023-09-300000318154-23-000064EDGAR—
2023-08-042023-06-300000318154-23-000053EDGAR—
2023-04-282023-03-310000318154-23-000029EDGAR—
2022-11-042022-09-300000318154-22-000055EDGAR—
2022-08-052022-06-300000318154-22-000041EDGAR—
2022-04-282022-03-310000318154-22-000021EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-190001193125-26-059490EDGAR17K words
2026-02-030000318154-26-000003EDGAR—
2026-01-300001193125-26-030518EDGAR—
2025-11-040000318154-25-000070EDGAR—
2025-08-050000318154-25-000054EDGAR—
2025-05-270000950170-25-077233EDGAR—
2025-05-010000318154-25-000018EDGAR—
2025-02-040000318154-25-000005EDGAR—
2024-10-300000318154-24-000042EDGAR—
2024-08-060000318154-24-000033EDGAR—

132 total filings indexed. 101 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc. ABOS — Acumen Pharmaceuticals, Inc.

Company Identity

CIK0000318154
TickerAMGN
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE
Websitehttps://www.amgen.com
Listed1983-06-17

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 619da399c680254c82d1858c56f842c2954795436876add14b5468665311b7e2
parent: b3328881994ca3c47079b13fcfcdf2bc69613f945acc5e8a64709b8cc5ce152f
content hash: e9eacf9bc9cf18fe5fd5532d2905e70f14a30acdd9575a2c501cb2bb20c9fade
signed: 2026-04-13T04:43:37.550Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf